Predictive low-glucose suspend system and glycemic variability

Introduction Predictive low-glucose suspend (PLGS) system helps prevent hypoglycemia. Aim To evaluate the effect of PLGS therapy on GV and percentage of time in range (TIR), time below range (TBR), and time above range (TAR) in pediatric type 1 diabetic patients. Method HbA 1c , coefficient of variation (CV), standard deviation (SD), and percentage of TIR, TBR, and TAR were evaluated in type 1 diabetic (T1D) pediatric patients followed up between Jan 2016 and Mar 2020 using PLGS system. Results Mean ages of diagnosis and duration of diabetes were 6.7 ± 4.1 and 8.2 ± 4.3 years, respectively. Nineteen of the patients were male (46.3%) and 22 were female (53.7%). Twenty-two (53.7%) of the patients were using low-glucose suspend system and 19 (46.3%) were on multiple daily injection therapy (MDI). On PLGS therapy, the 3rd, 6th, 9th, and 12th months’ HbA 1c of patients were not different from previous years’ mean HbA 1c in all participants. In the 3rd, 6th, 9th, and 12th months of PLGS therapy, % of TIR were 65.34 ± 14.75%, 65.80 ± 14.67%, 66.58 ± 11.21%, and 70.04 ± 10.16%, respectively ( p = 0.01). Although statistically insignificant, CV decreased from 36.33 to 34.30% and SD decreased from 60.14 to 58.60 in the 1-year follow-up period ( p = 0.062 and p = 0.246). Conclusion With PLGS therapy, TIR was > 70% and the time spent in hypoglycemia was very low.